Fragment-based Drug Discovery - Global Market Trajectory & Analytics

Global Fragment-based Drug Discovery Market to Reach $1.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Fragment-based Drug Discovery estimated at US$568 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at a CAGR of 10.4% over the period 2020-2027. Fragment Screening Technique, one of the segments analyzed in the report, is projected to record 11% CAGR and reach US$644.2 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Fragment Optimization Technique segment is readjusted to a revised 9.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $168.6 Million, While China is Forecast to Grow at 9.7% CAGR

The Fragment-based Drug Discovery market in the U.S. is estimated at US$168.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$195.6 Million by the year 2027 trailing a CAGR of 9.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.7% and 8.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Select Competitors (Total 44 Featured):

Astex Pharmaceuticals, Inc.
Beactica AB
Charles River Laboratories International, Inc.
Evotec AG
Sygnature Discovery Ltd.

Frequently Asked Questions about the Global Market for Fragment-based Drug Discovery

What is the estimated value of the Global Market for Fragment-based Drug Discovery?

The Global Market for Fragment-based Drug Discovery was estimated to be valued at $568 Million in 2020.

What is the growth rate of the Global Market for Fragment-based Drug Discovery?

The growth rate of the Global Market for Fragment-based Drug Discovery is 9.9%, with an estimated value of $1100 Million by 2027.

What is the forecasted size of the Global Market for Fragment-based Drug Discovery?

The Global Market for Fragment-based Drug Discovery is estimated to be worth $1100 Million by 2027.

Report Attribute	Details
No. of Pages	176
Published	April 2021
Forecast Period	2020 - 2027
Estimated Market Value ( USD ) in 2020	$ 568 Million
Forecasted Market Value ( USD ) by 2027	$ 1100 Million
Compound Annual Growth Rate	9.9%
Regions Covered	Global

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Current & Future Analysis for Fragment-based Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for Fragment-based Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Fragment-based Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
Table 4: World Current & Future Analysis for Fragment Screening Technique by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 5: World Historic Review for Fragment Screening Technique by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 6: World 15-Year Perspective for Fragment Screening Technique by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 7: World Current & Future Analysis for Fragment Optimization Technique by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 8: World Historic Review for Fragment Optimization Technique by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 9: World 15-Year Perspective for Fragment Optimization Technique by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 10: World Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 11: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 12: World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 13: World Current & Future Analysis for Contract Research Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 14: World Historic Review for Contract Research Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 15: World 15-Year Perspective for Contract Research Organization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 16: World Current & Future Analysis for Academic and Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 17: World Historic Review for Academic and Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 18: World 15-Year Perspective for Academic and Research Institutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 19: USA Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 20: USA Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 21: USA 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
Table 22: USA Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 23: USA Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 24: USA 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
CANADA
Table 25: Canada Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 26: Canada Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 27: Canada 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
Table 28: Canada Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 29: Canada Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 30: Canada 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
JAPAN
Table 31: Japan Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 32: Japan Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 33: Japan 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
Table 34: Japan Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 35: Japan Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 36: Japan 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
CHINA
Table 37: China Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 38: China Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 39: China 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
Table 40: China Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 41: China Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 42: China 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
EUROPE
Table 43: Europe Current & Future Analysis for Fragment-based Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 44: Europe Historic Review for Fragment-based Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 45: Europe 15-Year Perspective for Fragment-based Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Table 46: Europe Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 47: Europe Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 48: Europe 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
Table 49: Europe Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 50: Europe Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 51: Europe 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
FRANCE
Table 52: France Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 53: France Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 54: France 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
Table 55: France Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 56: France Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 57: France 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
GERMANY
Table 58: Germany Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 59: Germany Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 60: Germany 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
Table 61: Germany Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 62: Germany Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 63: Germany 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
ITALY
Table 64: Italy Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 65: Italy Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 66: Italy 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
Table 67: Italy Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 68: Italy Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 69: Italy 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
UNITED KINGDOM
Table 70: UK Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 71: UK Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 72: UK 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
Table 73: UK Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 74: UK Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 75: UK 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
REST OF EUROPE
Table 76: Rest of Europe Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 77: Rest of Europe Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 78: Rest of Europe 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
Table 79: Rest of Europe Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 80: Rest of Europe Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 81: Rest of Europe 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Table 82: Asia-Pacific Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 83: Asia-Pacific Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 84: Asia-Pacific 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
Table 85: Asia-Pacific Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 86: Asia-Pacific Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 87: Asia-Pacific 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027
REST OF WORLD
Table 88: Rest of World Current & Future Analysis for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 89: Rest of World Historic Review for Fragment-based Drug Discovery by Service Type - Fragment Screening Technique and Fragment Optimization Technique Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 90: Rest of World 15-Year Perspective for Fragment-based Drug Discovery by Service Type - Percentage Breakdown of Value Sales for Fragment Screening Technique and Fragment Optimization Technique for the Years 2012, 2020 & 2027
Table 91: Rest of World Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 92: Rest of World Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 93: Rest of World 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organization and Academic and Research Institutions for the Years 2012, 2020 & 2027

IV. COMPETITION

Total Companies Profiled: 44

What is the estimated value of the Global Market for Fragment-based Drug Discovery?

What is the growth rate of the Global Market for Fragment-based Drug Discovery?

What is the forecasted size of the Global Market for Fragment-based Drug Discovery?

Table of Contents

Related Topics

Related Reports

Fragment-based Drug Discovery Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 To 2029

Fragment-based Drug Discovery Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application

Growth Opportunities in Predictive Genetic Testing, AI Enabled Drug Discovery

Fc Fragment Of IgG Low Affinity III Receptor Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

IgG Receptor FcRn Large Subunit p51 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players